Key facts
- Abolis’s last known valuation is $53.1M.
- It has raised $40.1M; the latest was Later Stage VC ($38.8M) in Sep 2024.
- Notable investors include Evonik Venture Capital, BOLD (Business Opportunities for L'Oréal Development), Clay Capital (Singapore), DeepTech & Climate Fonds, Genopole — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Abolis
- ·The full record, as it builds
Funding rounds
No funding rounds for Abolis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Abolis
Developer of a microbial biotechnology platform designed to change production models of high-value molecules. The company offers advanced genetic tools, ML-driven pathway optimization, and scalable bioprocesses, enabling pharmaceutical and industrial manufacturers, cost-effective and sustainable production of complex molecules.
- Sector
- Healthcare
- HQ
- Paris, France
- Employees
- 84
- Website
- abolis.fr/
- Ownership
- Privately Held (backing)
Abolis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Abolis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Abolis in its N-PORT filings yet. We sweep new filings monthly.